AGO178

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Hepatic ImpairmentMajor Depressive Disorder

Phase 1

Pharmacokinetics of AGO178 in Participants With Liver Impairment

CompletedNCT01531309

Novartis PharmaceuticalsHepatic Impairment

Start: 2011-02-08End: 2011-09-02Updated: 2021-05-11

Phase 3

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

TerminatedNCT01156415

Novartis PharmaceuticalsMajor Depressive Disorder

Start: 2010-06-30End: 2011-10-31Updated: 2020-12-24